Oculis Holding AG Ordinary shares (OCS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Oculis Holding AG Ordinary shares stock (OCS) is currently trading at $25.00. Oculis Holding AG Ordinary shares PS ratio (Price-to-Sales) is 1189.67. Analyst consensus price target for OCS is $47.37. WallStSmart rates OCS as Sell.
- OCS PE ratio analysis and historical PE chart
- OCS PS ratio (Price-to-Sales) history and trend
- OCS intrinsic value — DCF, Graham Number, EPV models
- OCS stock price prediction 2025 2026 2027 2028 2029 2030
- OCS fair value vs current price
- OCS insider transactions and insider buying
- Is OCS undervalued or overvalued?
- Oculis Holding AG Ordinary shares financial analysis — revenue, earnings, cash flow
- OCS Piotroski F-Score and Altman Z-Score
- OCS analyst price target and Smart Rating
Oculis Holding AG
📊 No data available
Try selecting a different time range
Smart Analysis
Oculis Holding AG Ordinary shares (OCS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Oculis Holding AG Ordinary shares (OCS) Key Strengths (2)
Revenue surging 13600.00% year-over-year
57.72% held by institutions, strong professional interest
Supporting Valuation Data
Oculis Holding AG Ordinary shares (OCS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 1189.7x annual revenue
Very expensive at 5.8x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Oculis Holding AG Ordinary shares (OCS) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 13600.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (1189.67), Price/Book (5.83) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -73.50%, Operating Margin at -5020.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -73.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 13600.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OCS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OCS's Price-to-Sales ratio of 1189.67x sits near its historical average of 1223.07x (51th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 53% below its historical high of 2527.16x set in Feb 2026, and 153% above its historical low of 470.95x in Mar 2023. Over the past 12 months, the PS ratio has compressed from ~1616.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Oculis Holding AG Ordinary shares (OCS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Oculis Holding AG Ordinary shares is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 1M with 13600% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 13600% YoY, reaching 1M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 46M in cash.
Free cash flow is -16M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Oculis Holding AG Ordinary shares maintain 13600%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Oculis Holding AG Ordinary shares.
Bottom Line
Oculis Holding AG Ordinary shares is a high-conviction growth story with revenue accelerating at 13600% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:28:18 AM
About Oculis Holding AG Ordinary shares(OCS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.